The purpose of the study is to investigate the safety and the recommended dose for later use
of an oncolytic adenovirus CGTG-102 in combination with low-dose oral cyclophosphamide in the
treatment of advanced cancers.
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT01598129
Ages eligible for Study
18 Years and older
Genders eligible for Study
Accepts Healthy Volunteers
Solid tumour refractory to evidence-based oncological therapies.
Age 18 years and over.
At least one tumour mass measurable by PET (i.e. PET-positive lesion that can reliably be assessed for SUVmax, typically featuring longest diameter ≥2 cm).
Tumour is injectable i.t. by direct visualisation/palpation or by imaging-guidance
(ultrasound). I.t. includes intracavitary injections, particularly intraperitoneal and intrapleural.
Histological confirmation of primary disease or relapse.
Patient has given signed informed consent.
WHO performance score 0-1 and life expectancy more than 3 months.
Previous anti-cancer treatment at least 1 month before Day 1.
Tumour assessed to be suitable for biopsy.
Hepatic, renal and bone marrow functions within normal limits for the target population as indicated by the following:
Total bilirubin ≤ the upper limit of normal (ULN).
ASAT, ALAT ≤3.0 × ULN.
Serum creatinine ≤1.5 x ULN.
International normalised ratio (INR) ≤1.5 x ULN.
Haematologic parameters: Patients can be transfused to meet the haemoglobin and platelet count entry criteria.
Haemoglobin ≥10 g/dL
Leucocytes ≥2.3 x 109/L
Platelet count ≥7.5 x 109/L
Use of high dose systemic immune suppressive medication within 3 weeks of anticipated first treatment. Note: patients taking low-dose corticosteroids for the treatment of nausea and/or taking maintenance corticosteroids are permitted to enrol.
Known infection with HIV or known underlying genetic immunodeficiency disease as these might affect the safety and efficacy of treatment.
Treatment of the injected tumour(s) with radiotherapy, chemotherapy, surgery, or an investigational drug within 4 weeks prior to the first treatment.
Clinically significant active infection or clinically significant medical condition considered high risk for investigational new drug treatment (e.g. pulmonary, neurological, cardiovascular, metabolic, clinically significant and/or rapidly accumulating pericardial effusion).
Severe or unstable cardiac disease.
Known brain metastases, glioma. Central nervous system malignancy, including carcinomatosis meningitis.
Pulse oximetry oxygen saturation <90% at rest in room air.
Vaccination with a live virus (i.e. measles, mumps, rubella, etc.) <30 days prior to the first treatment.
History of hepatic dysfunction, cirrhosis or hepatitis.
Prior organ transplant.
Pregnant or lactating patients.
Evidence of coagulation disorder.
Other conditions which, in the opinion of the investigator, might interfere with the study findings or represent a safety hazard for the patient.
All locations for NCT01598129
Helsinki, Finland, 00180
Trial results for NCT01598129
Participant Flow: Overall Study
3 / 12
Completed / Started
Serious Adverse Events
5 / 12
Affected / At Risk
Other Adverse Events
12 / 12
Affected / At Risk
View full eligibility
Tris trial is registered with FDA with number: NCT01598129. The sponsor of the trial is Targovax Oy and it is looking for 12 volunteers for the current phase.
Official trial title: Exploratory Open Label Study of GM-CSF Coding Oncolytic Adenovirus CGTG-102, With Low Dose Cyclophosphamide in Patients With Refractory Injectable Solid Tumours
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Thank you for applying!
We'll contact you soon with more information.
Consult your doctor?
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.